Gijs Klarenbeek News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Gijs klarenbeek. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Gijs Klarenbeek Today - Breaking & Trending Today

Sequana Medical N : announces additional alfapump data supporting strong and durable clinical profile; PMA on track for year-end submission -October 19, 2023 at 01:53 am EDT

REGULATED INFORMATION - INSIDE INFORMATION

19 October 2023, 07:00 am CEST

One-year alfapump data from POSEIDON shows safety and. ....

United States , Cian Crosbie , Gijs Klarenbeek , Health Solutions , Company Or Sequanamedical , American Consortium For The Study Of End , Sequana Medical , Euronext Brussels , Senior Medical Advisor , Chief Executive Officer , Major Adverse Events , Patient Preference , Pivotal Cohort , North American Consortium , End Stage Liver Disease , North America , Conference Call , North American , Pre Market Approval , Glomerular Filtration Rate , Institutional Review ,

Sequana Medical Announces the Completion of alfapump Implantations in POSEIDON, the North American Pivotal alfapump Study

Sequana Medical Announces the Completion of alfapump Implantations in POSEIDON, the North American Pivotal alfapump Study
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.

United States , New Zealand , Hong Kong , United Kingdom , Kaplan Meier , Cian Crosbie , Gijs Klarenbeek , Guillaume Van Renterghem , Company Or Sequana , Clinical Events Committee , Liver International , Euronext Brussels , North American , Pivotal Cohort , Roll In Cohort , Chief Executive Officer , Senior Medical Adviser , Clinical Events , Direct Sodium Removal , Sequana Medical ,

Sequana Medical NV: Sequana Medical announces the completion of alfapump implantations in POSEIDON, the North American pivotal alfapump study

Reporting of primary endpoint on track for Q4 2022FDA regulatory submission on track for mid-202370% survival of POSEIDON Roll-In patients at one year post-implantation1 compares favourably ....

United States , New Zealand , Hong Kong , United Kingdom , Kaplan Meier , Cian Crosbie , Gijs Klarenbeek , Guillaume Van Renterghem , Company Or Sequana , Liver International , Euronext Brussels , North American , Pivotal Cohort , Roll In Cohort , Chief Executive Officer , Sequana Medical , Senior Medical Adviser , Direct Sodium Removal ,

Sequana Medical announces the completion of alfapump

Reporting of primary endpoint on track for Q4 2022FDA regulatory submission on track for mid-202370% survival of POSEIDON Roll-In patients at one year. ....

United States , New Zealand , Hong Kong , United Kingdom , Kaplan Meier , Cian Crosbie , Gijs Klarenbeek , Guillaume Van Renterghem , Company Or Sequana , Clinical Events Committee , Liver International , Sequana Medical , Euronext Brussels , North American , Pivotal Cohort , Roll In Cohort , Chief Executive Officer , Senior Medical Adviser , Clinical Events , Direct Sodium Removal , Sequana Medical Nv ,